recombinant protein expression

Cloning a gene puts a useful instruction into a cell, but instructions on a shelf do nothing — you want the cell to actually read them and build the product. Recombinant protein expression is the payoff step: getting a host cell to transcribe and translate a cloned gene so it churns out the protein that gene encodes, often in large amounts.

You start with an expression vector — a plasmid that, unlike a plain cloning vector, carries the signals a host needs to make protein: a strong promoter to drive transcription, a ribosome binding signal, and often a controllable switch so you can turn expression on at the right moment. You insert your gene (usually as intron-free cDNA), transform the host, grow a large culture, then flip the switch (for example, add the inducer IPTG) to command the cells to pour out your protein. The host reads the foreign gene with its own machinery and assembles the protein. E. coli is the cheap, fast workhorse, but it cannot perform many eukaryotic finishing touches (like adding sugar chains or certain folds), so human therapeutic proteins are often made in yeast or mammalian cells instead — chosen so the protein is folded and modified correctly.

This is the step that delivers the practical promise of recombinant DNA. Before it, human proteins for medicine had to be extracted in tiny amounts from tissue. Recombinant insulin (Humulin, 1982) was the first recombinant drug: the human insulin gene expressed in bacteria, giving a limitless, consistent supply that replaced animal-derived insulin. The same approach now produces human growth hormone, clotting factors, antibodies, and many enzymes — and it underlies the production of countless research proteins and even the leap to transgenic organisms that express a chosen gene throughout their bodies.